

## Amelioration of human neutrophil elastase-induced emphysema in hamsters by pretreatment with an oligopeptide chloromethyl ketone

E.C. Lucey, P.J. Stone, J.C. Powers, G.L. Snider

*Amelioration of human neutrophil elastase-induced emphysema in hamsters by pretreatment with an oligopeptide chloromethyl ketone. E.C. Lucey, P.J. Stone, J.C. Powers, G.L. Snider.*

**ABSTRACT:** Human neutrophils are a likely source of elastase in the pathogenesis of human pulmonary emphysema. A study was undertaken to determine whether emphysema, induced in hamsters by intratracheal treatment with human neutrophil elastase (HNE), could be ameliorated by intratracheal instillation of succinyl-alanyl-alanyl-prolyl-valine-chloromethyl ketone (CMK). One mg of CMK was given to hamsters 1 h before 300 or 360 µg HNE or 1 h or 4 h after 360 µg HNE. The animals were studied eight weeks after treatment. The CMK given 4 h after HNE did not ameliorate the emphysema. The CMK given 1 h before HNE, ameliorated the development of emphysema but not bronchial secretory cell metaplasia. A molar ratio of instilled CMK to HNE of 128 was required for 50% *in vivo* effectiveness in ameliorating emphysema. Clearance studies indicated that 6.9% of the instilled CMK could be lavaged from the lungs 1 h after instillation. Therefore, an 8.9 to 1 molar ratio of lavageable CMK to HNE, at the time of HNE instillation, resulted in 50% protection. Using an *in vitro* assay with <sup>3</sup>H-elastin as substrate, a 3 to 1 molar ratio of CMK to HNE was required to inhibit 50% of the elastolytic activity; 14% of the activity remained with an 18 to 1 molar ratio of CMK to HNE. Study of the *in vivo* effectiveness of anti-elastases, given as pretreatment in ameliorating HNE-induced emphysema and secretory cell metaplasia, is a reasonable bioassay, which may be used as a step in evaluating such agents for possible use in the prevention of human disease.

*Eur Respir J.*, 1989, 2, 421-427.

Pulmonary Center and Dept of Biochemistry, Boston University School of Medicine, and Pulmonary Section, Boston Veterans Administration Medical Center, Boston, Massachusetts and Dept of Chemistry, Georgia Institute of Technology, Atlanta, Georgia.

Correspondence: Dr. E.C. Lucey, Research-Pulmonary #151, V.A. Medical Center, 150 S. Huntington Ave, Boston, MA 02130, USA.

**Keywords:** Bronchitis; chloromethyl ketone; elastic tissue; hamsters; human neutrophil elastase; neutrophils; porcine pancreatic elastase; pulmonary emphysema; secretory cells; secretory cell metaplasia.

Received: August, 1988; accepted after revision November 27, 1988.

Supported by the Veterans Administration Research Service and by Grants No. HL-19717, HL-25229 and HL-29307 from the National Heart, Lung and Blood Institute.

It has been shown that intratracheal instillation of succinyl-alanyl-alanyl-prolyl-valine-chloromethyl ketone (CMK) moderates the emphysema induced in hamsters by intratracheal instillation of porcine pancreatic elastase (PPE) [1]. Other oligopeptide chloromethyl ketone compounds have also been found to be effective in ameliorating PPE-induced emphysema when given orally [2] or intraperitoneally [3, 4]. When a crude extract of human neutrophils was used to induce emphysema, an oligopeptide chloromethyl ketone compound, given by aerosol, ameliorated the emphysema induced [5].

Human neutrophil elastase (HNE) induces much less severe emphysema than an equivalent dose of PPE, whether equivalence is based on moles of elastase or *in vitro* elastolytic activity [6-8]. Both enzymes induce secretory cell metaplasia in hamsters [8, 9]. Using a living smooth muscle cell culture as a substrate, HNE exhibited a 10-fold lower elastolytic activity as compared with PPE [10]. With purified elastin substrates HNE and PPE exhibit different peptide bond specificities but similar elastolytic activity. In view of these results and the fact that human neutrophils are a probable source of elastase in the pathogenesis of emphysema, it seemed appropriate to determine whether emphysema and secretory cell metaplasia

induced by purified HNE could be ameliorated by intratracheally administered CMK and whether the effectiveness of CMK in preventing elastolysis *in vitro* was helpful in predicting the *in vivo* effectiveness in the HNE-induced emphysema model.

### Materials and methods

#### *In vitro*

Human neutrophil elastase (HNE) (29 kd) was purified from purulent sputum by the method of MARTODAM *et al.* [11]. The amino acid composition of our preparations was similar to that reported by TWUMASI and LIENER [12], with a mean deviation in residues per mole of 1.4. There was a single band with a molecular mass of 29 kd on a sodium dodecyl sulphate polyacrylamide gel and there were 4 bands in close proximity that stained for protein, carbohydrate and elastase-like activity on an analytical disc gel (pH 4.5). Our preparation was 98±4% (mean±SEM, n=8) active as determined by active site titration [13].



The optical density at 280 nm was used to determine the enzyme concentration in solutions,

$$E_{1 \text{ cm}, 280 \text{ nm}}^{1\%} = 9.85.$$

Porcine pancreatic elastase (PPE) was prepared according to the method of SHOTTON [14] and assayed as previously described [15, 16]. It exhibited greater than 90% activity.

The succinyl-alanyl-alanyl-prolyl-valine-chloromethyl ketone (CMK) (488 daltons) was synthesized according to published procedures [17]. It readily dissolved in 0.15 M saline and was used within 30 min.

The *in vitro* inhibitory effectiveness of the CMK was assessed using a modification of a standard elastolytic assay procedure, omitting sodium dodecyl sulphate [18]. Briefly, culture tubes containing 5 mg of  $^3\text{H}$ -insoluble ligamentum nuchae elastin, an excess of substrate that produced a near maximal rate, and 4 ml of filtered (0.22  $\mu\text{m}$ ) assay buffer (50 mM sodium phosphate, pH 7.35, 140 mM sodium chloride, 0.5  $\text{mg}\cdot\text{ml}^{-1}$  bovine serum albumin) were incubated for 4 h at 37°C, alone (blank) or with 10  $\mu\text{g}$  HNE or 10  $\mu\text{g}$  of PPE. To other tubes, increasing amounts of CMK were added before the elastases.

After incubation the supernatants were filtered and assessed for  $^3\text{H}$ -elastin peptides by liquid scintillation spectrometry. The concentration of CMK resulting in 50% inhibition ( $\text{IC}_{50}$ ) of the HNE was determined by interpolation. In the absence of inhibitor, 1 nmol of HNE solubilized 407  $\mu\text{g}\cdot\text{h}^{-1}$  of elastin, whereas 1 nmol of PPE solubilized 186  $\mu\text{g}\cdot\text{h}^{-1}$  of elastin. The stability of the CMK in the assay system was assessed by preincubating CMK (384 nmol) for 1 h at 37°C in the culture tube containing elastin and buffer before adding HNE and incubating for an additional 4 h. Controls included tubes to which CMK was added followed immediately by HNE and a 4 h incubation period.

$^{14}\text{C}$ -CMK (2.58  $\text{mCi}\cdot\text{mmol}^{-1}$ ; MW of 490) was prepared by reaction of H-ala-ala-pro-val- $\text{CH}_2\text{Cl}$  with  $^{14}\text{C}$ -succinic anhydride [17] and used for active site titration of the elastases as follows. Three mg of HNE or PPE was incubated with 1.5 mg of  $^{14}\text{C}$ -CMK in assay buffer without albumin at 4°C for 16 h, then at 37°C for 1 h, and dialysed at 4°C. The concentration of elastase was determined from the absorption of light at 280 nm. Aliquots were assessed for radioactivity and elastolytic activity.

Alkylation of bovine serum albumin by CMK was assessed by incubating 15 nmol of albumin with 239 nmol of  $^{14}\text{C}$ -CMK for 15 min at 37°C in 1 ml of column buffer (0.05 M tris, pH 7.6, 0.6 M NaCl, 0.05%  $\text{NaN}_3$ ). The solution was loaded on a column packed with Sephadex G-100 that had been calibrated with molecular weight standards. Eluted material was collected using a fraction collector and fractions were assessed for radioactivity. Non-specific alkylation of HNE that had been previously treated with unlabelled CMK, dialysed and lyophilized (HNE-CMK) was assessed by incubating 17

nmol of HNE-CMK with 220 nmol of  $^{14}\text{C}$ -CMK and chromatographing as above.

#### *In vivo*

Retention in the lungs of functionally active CMK after instillation was studied as follows. Three hamsters were instilled with 0.5 ml of saline containing 1 mg of freshly dissolved CMK. Another three hamsters received saline only. One hour after instillation, each hamster was anaesthetized with sodium pentobarbital and the lungs lavaged three times with 5 ml aliquots of saline as previously described [15]. Bronchoalveolar lavage (BAL) fluid was centrifuged to remove the cells. The amount of functionally active CMK present in the BAL supernatant was estimated by comparing inhibition of HNE with a standard inhibitor curve after correction for inhibition obtained with the control BAL (almost negligible). These data were used to calculate the half-life of CMK in the BAL assuming second order disappearance kinetics as we have previously found for PPE-CMK [15] and eglin-c [19]. Second order kinetics uses the relationship:

$$\frac{1}{C} - \frac{1}{C_0} = k \cdot t$$

where  $C_0$  is the amount at the start, C is the amount t min later and k is the constant.

To determine the protective effects of CMK against HNE-induced emphysema, 84 male, Syrian, golden hamsters, *Mesocricetus auratus* (Engle Laboratory Animals, Inc., Farmersburg, IN) were given two transoral intratracheal injections, 1 or 4 h apart. The animals were anaesthetized by  $\text{CO}_2$  inhalation before each administration of either 0.5 ml of saline or a saline solution containing 1 mg of CMK, 300  $\mu\text{g}$  of HNE or 360  $\mu\text{g}$  of HNE.

These experiments were carried out in two parts. In the first protocol the effects of CMK given 1 h before, 1 h after or 4 h after 360  $\mu\text{g}$  of elastase were studied. There was a high mortality among the animals given 360  $\mu\text{g}$  of HNE followed in 1 h by CMK (6 out of 8 died) or by saline (4 out of 8 died). There were also two deaths among the eight animals given 360  $\mu\text{g}$  of HNE followed in 4 h by CMK. Another hamster died after receiving 360  $\mu\text{g}$  of HNE 1 h after CMK. All deaths were due to pulmonary haemorrhage and occurred within 4 h of the second treatment. In the second protocol only the effect of pretreatment with CMK 1 h before HNE was investigated and the dose of elastase was lowered to 300  $\mu\text{g}$  in order to reduce the probability of death. There were no deaths in this protocol.

All animals were studied 56 days after treatment. Lung volumes and quasi-static deflation pressure-volume relationships were measured in animals anaesthetized with sodium pentobarbital. Details of the procedure have been published elsewhere [8, 20]. After completion of the physiological measurements, the animals were



exsanguinated. The lungs were inflation fixed, *in situ*, by injecting a volume of fixative (4% formalin, 1% glutaraldehyde) equal to the animal's inspiratory capacity. Transverse sections of the left lungs were embedded in paraffin and 5–6  $\mu\text{m}$  sections were stained for microscopic examination with haematoxylin and eosin (H&E) or with the alcian-blue periodic-acid-Schiff reaction (AB-PAS). The secretory cell index (SCI), a semi-quantitative grading from 0–4 of secretory cell metaplasia [9], and the mean linear intercept (MLI) were determined on the AB-PAS and H&E stained slides, respectively. The MLI was measured by projection microscopy on 30 fields, 10 randomly selected fields from each of the 3 sections.

The effectiveness of CMK was assessed by calculating an index of effectiveness using a 50% weighting for anatomical severity of emphysema (determined by the MLI) and 50% weighting for functional abnormalities suggesting emphysema (determined by functional residual capacity (FRC) and vital capacity (VC)) [13].

The SCI data were analysed statistically by the non-parametric Kruskal Wallis test [21]. Differences among means of the other data were analysed by Students t-test and analysis of variance [22]. Probability values of  $p < 0.05$  were considered significant. Values are expressed as mean  $\pm$  SEM.

**Results**

*In vitro*

CMK was stable in our *in vitro* assay. When CMK was incubated in the presence of substrate and buffer for 1 h before adding the HNE, there was no detectable loss of inhibitory activity as compared to the standard procedure of adding CMK immediately before the HNE (54.4  $\pm$  0.7% inhibition,  $n=3$ , as compared with 58.8  $\pm$  2.4% inhibition,  $n=3$ , respectively).




Fig. 1. – Examples of the titration of 10  $\mu\text{g}$  HNE (open triangles) and PPE (open circles) by CMK, showing the percentage inhibition of elastolytic activity against  $^3\text{H}$ -elastin substrate. The dash lines are linear extrapolations of the steep portions of the plots. HNE: human neutrophil elastase; PPE: porcine pancreatic elastase; CMK: succinyl-alanyl-alanyl-prolyl-valine-chloromethyl ketone.

There appears to be a sharp inflection in the curves relating percentage inhibition to a molar ratio (fig. 1). For HNE this inflection occurred at a molar ratio of about 4 (60% inhibition), and for PPE at a molar ratio of about 1.6 (80% inhibition). At higher molar ratios the increase in inhibition with added inhibitor was much less. For PPE there was complete inhibition at a molar ratio of about 7.7; CMK appeared unable to completely inhibit HNE even at CMK to HNE molar ratios as high as 18 to 1.

A least squares analysis of the steeper portion of the plots, indicates that 261  $\pm$  35 nM CMK (mean of 2 determinations) was required to inhibit 50% of the elastolytic activity of 88 nM HNE (a 3 to 1 molar ratio of CMK to HNE). For PPE a molar ratio of 0.7 was sufficient for 50% inactivation. The regression line extrapolated to 100% inhibition with a CMK/HNE molar ratio of 7.4 ( $r = -0.99$ ) and a CMK/PPE molar ratio of 1.3 ( $r = -0.99$ ).




Fig. 2. – Bar diagram showing the effect of treatment with 1.0 mg of suc-ala-ala-pro-val-chloromethyl ketone (CMK), 1 h before human neutrophil elastase (HNE), on the mean  $\pm$  SEM values of mean linear intercept (MLI) for six groups of hamsters. The data are from two experiments using two different doses of HNE. The values for the three groups in the protocol using 360  $\mu\text{g}$  of HNE are represented by solid dark bars, the values for the three groups in the protocol using 300  $\mu\text{g}$  of HNE are represented by the open bars. The diamond indicates a significant difference of the saline-1 h-HNE groups from the saline-1 h-saline groups and the CMK-1 h-HNE groups. Sample sizes are in parentheses.

Incubation of HNE with  $^{14}\text{C}$ -CMK resulted in a  $^{14}\text{C}$  radioactivity peak that co-eluted with HNE during chromatography. With saturating amounts of  $^{14}\text{C}$ -CMK the HNE- $^{14}\text{C}$ -CMK complex had a specific radioactivity of 2.12  $\pm$  0.04 mCi  $\cdot$  mmol $^{-1}$  ( $n=4$ ), 82  $\pm$  2% of that of the  $^{14}\text{C}$ -CMK preparation. The HNE- $^{14}\text{C}$ -CMK complex was

devoid of elastolytic activity. The  $^{14}\text{C}$ -labelled PPE exhibited specific radioactivity of  $2.01 \pm 0.23 \text{ mCi}\cdot\text{mmol}^{-1}$  ( $n=2$ ) and no measurable elastolytic activity. The irreversibility as well as the specificity of the labelling of HNE by CMK was also demonstrated by the following experiment. When HNE-CMK was incubated with  $^{14}\text{C}$ -CMK and chromatographed, no measurable  $^{14}\text{C}$  radioactivity co-eluted with the HNE-CMK. In the experiment with albumin only 0.5% of the radioactivity co-eluted with the albumin.




Fig. 3. - Bar diagram showing the effect of treatment with 1 mg of CMK, 1 h before HNE, on the mean  $\pm$  SEM values of total lung capacity ( $\text{TLC}_{25}$ ), functional residual capacity (FRC), and residual volume ( $\text{RV}_{-20}$ ). The star indicates a significant difference from the appropriate saline-1 h-saline control group. The diamonds indicate a significant difference from both the saline-1 h-saline and CMK-1 h-HNE groups.  $\text{TLC}_{25}$ : total lung capacity at 25  $\text{cmH}_2\text{O}$  transpulmonary pressure;  $\text{RV}_{-20}$ : residual volume at -20  $\text{cmH}_2\text{O}$  transpulmonary pressure; FRC: functional residual capacity; VL: lung gas volume. For other abbreviations see legend of figure 1.

#### In vivo

One hour after instillation of CMK, 6.9% could be lavaged out as functionally active. This gives a 4.5 min half-life for CMK in the lavage compartment using second order disappearance kinetics:

$$\{t_{1/2} = (1/50\% - 1/100\%) / 2.25 \times 10^{-3} \cdot \text{min}^{-1} \cdot \%^{-1}\}.$$

The intratracheal instillation of either 300 or 360  $\mu\text{g}$  of HNE caused emphysema. Hamsters given saline, followed in 1 h by 360  $\mu\text{g}$  of HNE, had an approximate 63% increase in MLI above the mean for control animals

receiving saline followed in 1 h by saline (fig. 2). The total lung capacity at 25  $\text{cmH}_2\text{O}$  transpulmonary ( $\text{TLC}_{25}$ ) increased by about 24% and the functional residual capacity (FRC) increased by approximately 60% (fig. 3). Hamsters given 300  $\mu\text{g}$  of HNE 1 h after saline had a 34% increase in MLI (fig. 2), a 15% increase in  $\text{TLC}_{25}$ , and a 43% increase in FRC (fig. 3). All of these differences were significant.

Pretreatment of hamsters with CMK 1 h before 300 or 360  $\mu\text{g}$  of HNE ameliorated the emphysema. The mean values for MLI, FRC and residual volume at a transpulmonary pressure of -20  $\text{cmH}_2\text{O}$  ( $\text{RV}_{-20}$ ) were significantly less in the CMK followed in 1 h by HNE (360 and 300  $\mu\text{g}$ ) groups than in the saline followed in 1 h by HNE (360 and 300  $\mu\text{g}$ ) groups, respectively (figs 2 and 3).




Fig. 4. - Bar diagram showing the effect of treatment with CMK, after HNE, on the mean  $\pm$  SEM of mean linear intercept (MLI) for five groups of hamsters: two intratracheal injections of saline, 1 h apart (saline-1 h-saline); 360  $\mu\text{g}$  HNE followed in 1 h by 1.0 mg of CMK (HNE-1 h-CMK); 360  $\mu\text{g}$  of HNE followed in 4 h by CMK (HNE-4 h-CMK). A star indicates a significant difference from the saline-1 h-saline group. Because there were only two surviving animals in the HNE-1 h-CMK group, statistical analysis of this group was not attempted. The sample sizes are in parentheses. For other abbreviations see legend of figure 1.

The 1 mg dose of CMK had an index of effectiveness of 65% against 360  $\mu\text{g}$  HNE and 77% against 300  $\mu\text{g}$  HNE. Interpolation to 50% effectiveness (using these two points and the origin and assuming a linear relationship) indicates that a CMK to HNE molar ratio of 128 is required. Since 6.9% of the CMK was recovered in a







molar ratio of CMK to HNE required for an index of effectiveness of 50% was 128, which is considerably higher than the molar ratio of 3.3 for eglin-c [13], under comparable conditions. This 40-fold lower efficiency of CMK *in vivo* compared to eglin-c is not fully explained by the inhibitory capacities of the agents seen *in vitro*. At  $IC_{50}$  the inhibitor/HNE molar ratio was 3.0 for CMK, compared to 0.5 for eglin-c [13], only a 6-fold change.

Possible explanations for the lower than expected *in vivo* efficiency of CMK compared to eglin-c include the more rapid clearance of the much smaller CMK molecule from the lungs during the 1 h interval between administration of inhibitor and HNE; the inactivation of CMK in the lungs by peptidases; or alkylation reactions and destruction of the inhibitor by reaction with physiological nucleophiles. Both ends of the CMK molecule are blocked and it should thus be inert to carboxypeptidases and aminopeptidases. An elastase could cleave the ala-ala bond of CMK, but the presence of the pro residue practically precludes this possibility. CMK has a 4.5 min functional half-life in the lavageable compartment of the lungs as compared with more than 35 min for eglin-c [19].

Using the BAL clearance data to estimate the amount of CMK present in the lungs 1 h after instillation, the molar ratio of CMK to HNE required in the lung at the time of HNE instillation for 50% protection from emphysema induction was 8.9. The inefficiency of the CMK *in vivo* as compared to *in vitro* can be expressed as the above mentioned molar ratio divided by the molar ratio of CMK to HNE required for 50% *in vitro* inhibition of elastolysis; for CMK the inefficiency is  $8.9/3.0=2.9$  as compared to  $1.25/0.5=2.5$  for eglin-c [19].

Oligopeptide chloromethyl ketones are highly reactive and potentially toxic molecules [29] that will never find a use as prophylactic agents in human emphysema and airway hypersecretion. Their irreversible inactivation of HNE is useful in exploring the *in vivo* behaviour of anti-elastases and modes of therapeutic intervention in animal models of emphysema [24, 30]. The current study and a previous one [19] indicate that post-treatment with an anti-elastase is not an effective protocol for the measurement of *in vivo* effectiveness of anti-elastases against HNE. Study of the *in vivo* effectiveness of anti-elastases, given as pretreatment in ameliorating HNE-induced emphysema and secretory cell metaplasia is a reasonable bioassay, which may be used as a step in evaluating such agents for possible use in the prevention of human disease.

**Acknowledgements:** The authors thank A. Catanese, J.D. Calore, F. Barnard and B.D. Clark for their expert assistance.

## References

1. Stone PJ, Lucey EC, Calore JD, Snider GL, Franzblau C, Costillo MJ, Powers JC. – The moderation of elastase-induced emphysema in the hamster by intratracheal pretreatment or post-treatment with succinyl-alanyl-alanyl-prolyl-valine-chloromethyl ketone. *Am Rev Respir Dis*, 1981, 124, 56–59.
2. Janoff A, Dearing R. – Prevention of elastase-induced experimental emphysema by oral administration of a synthetic elastase inhibitor. *Am Rev Respir Dis*, 1980, 121, 1025–1029.
3. Kleinerman J, Ranga V, Rynbrandt D, Ip MPC, Sorensen J, Powers JC. – The effect of the specific elastase inhibitor, alanyl-alanyl-prolyl-alanine-chloromethyl ketone, on elastase-induced emphysema. *Am Rev Respir Dis*, 1980, 121, 381–387.
4. Ip MPC, Kleinerman J, Ranga V, Sorensen J, Powers JC. – The effects of small doses of oligopeptide elastase inhibitors on elastase-induced emphysema in hamsters: a dose-response study. *Am Rev Respir Dis*, 1981, 124, 714–717.
5. Tarjan E, Peto L, Appel J, Tolnay P. – Prevention of elastase-induced emphysema by aerosol administration of a specific synthetic elastase inhibitor. *Eur J Respir Dis*, 1983, 64, 442–448.
6. Janoff A, Sloan B, Weinbaum G, Damiano V, Sandhaus RA, Elias J, Kimbel P. – Experimental emphysema induced with purified human neutrophil elastase: tissue localization of the instilled protease. *Am Rev Respir Dis*, 1977, 115, 461–478.
7. Senior RM, Tegner H, Kuhn C, Ohlsson K, Starcher BC, Pierce JA. – The induction of pulmonary emphysema with human leukocyte elastase. *Am Rev Respir Dis*, 1977, 116, 469–475.
8. Snider GL, Lucey EC, Christensen TG, Stone PJ, Calore JD, Catanese A, Franzblau C. – Emphysema and bronchial secretory cell metaplasia induced in hamsters by human neutrophil products. *Am Rev Respir Dis*, 1984, 129, 155–160.
9. Christensen TG, Korthy AL, Snider GL, Hayes JA. – Irreversible bronchial goblet cell metaplasia in hamsters with elastase-induced panacinar emphysema. *J Clin Invest*, 1977, 59, 397–404.
10. Stone PJ, McMahon MP, Morris SM, Calore JD, Franzblau C. – Elastin in a neonatal rat smooth muscle cell culture has greatly decreased susceptibility to proteolysis by human neutrophil elastase. An *in vitro* model of elastolytic injury. *In Vitro Cellular Developmental Bio*, 1988, 23, 663–676.
11. Martodam RR, Baugh RJ, Twumasi DY, Liener IE. – A rapid procedure for the large scale purification of elastase and cathepsin G from human sputum. *Prep Biochem*, 1979, 9, 15–31.
12. Twumasi DY, Liener IE. – Proteases from purulent sputum. Purification and properties of the elastase and chymotrypsin like enzymes. *J Biol Chem*, 1977, 252, 1917–1926.
13. Snider GL, Stone PJ, Lucey EC, Breuer R, Calore JD, Seshardi T, Catanese A, Maschler R, Schnebli HP. – Eglin-c, a polypeptide derived from the medicinal leech, prevents human neutrophil elastase-induced emphysema and bronchial secretory cell metaplasia in the hamster. *Am Rev Respir Dis*, 1985, 132, 1155–1161.
14. Shotton DM. – Elastase. In: *Methods in Enzymology*. G.E. Perlman and L. Lorand eds. Academic Press, New York, 1970, pp. 113–140.
15. Stone PJ, Calore JD, Snider GL, Franzblau C. – The dose dependent fate of enzymatically active and inactivated tritiated methylated pancreatic elastase administered intratracheally in the hamster. *Am Rev Respir Dis*, 1979, 120, 577–587.
16. Stone PJ, Calore JD, Snider GL, Franzblau C. – Role of alpha-macroglobulin-elastase complexes in the pathogenesis of elastase-induced emphysema in hamsters. *J Clin Invest*, 1982, 69, 920–931.
17. Powers JC, Gupton BF, Hartley AD, Nishino N, Whitley RJ. – Specificity of porcine pancreatic elastase, human leukocyte elastase and cathepsin G. Inhibition with peptide chloromethyl ketones. *Biochem Biophys Acta*, 1977, 485, 156–166.
18. Stone PJ, Franzblau C, Kagan HM. – Proteolysis of insoluble elastin. *Methods Enzymol*, 1982, 82a, 588–605.



19. Lucey EC, Stone PJ, Christensen TG, Breuer R, Calore JD, Snider GL. – Effect of varying the time interval between intratracheal administration of eglin-c and human neutrophil elastase on prevention of emphysema and secretory cell metaplasia in hamsters. With observations on the fate of eglin-c and the effect of repeated instillations. *Am Rev Respir Dis*, 1986, 134, 471–475.
20. Lucey EC, Stone PJ, Christensen TG, Breuer R, Snider GL. – An 18 month study of the effects on hamster lungs of intratracheally administered human neutrophil elastase. *Exp Lung Res*, 1988, 14, 671–686.
21. Noether GE. – *In*: Introduction to statistics. Houghton Mifflin Co., Boston, 1971, pp. 143–150.
22. Snedecor GW, Cochran WG. – *In*: Statistical methods. Ames, Iowa State University Press, Iowa, 1967, pp. 258–298.
23. Powers JC, Harper JW. – Inhibitors of serine proteases. *In*: Proteinase Inhibitors. A.J. Barrett and G.S. Salvesen eds, Elsevier, New York, 1986, pp. 55–152.
24. Powers JC. – Synthetic elastase inhibitors: prospects for use in the treatment of emphysema. *Am Rev Respir Dis*, 1983, 127, S54–S58.
25. Kezdy FJ, Thomson A, Bender ML. – Studies on the reaction of chymotrypsin and L-1-chloro-3-tosylamido-4-phenyl-2-butanone. *J Am Chem Soc*, 1967, 89, 1004–1009.
26. Stone PJ, Calore JD, Franzblau C. – Release of human neutrophil elastase from alpha-2-macroglobulin complexes containing human neutrophil elastase. *Am NY Acad Sci*, 1983, 421, 398–400.
27. Breuer R, Lucey EC, Stone PJ, Christensen TG, Snider GL. – Proteolytic activity of human neutrophil elastase and porcine pancreatic trypsin causes bronchial secretory cell metaplasia in hamsters. *Exp Lung Res*, 1985, 9, 167–175.
28. Lucey EC, Stone PJ, Breuer R, Christensen TG, Calore JD, Catanese A, Franzblau C, Snider GL. – Effect of combined human neutrophil cathepsin G and elastase on induction of secretory cell metaplasia and emphysema in hamsters, with *in vitro* observations on elastolysis by these enzymes. *Am Rev Respir Dis*, 1985, 132, 362–366.
29. Ranga V, Kleinerman J, Ip MPC, Sorensen J, Powers JC. – Effects of oligopeptide chloromethyl ketone administered after elastase: renal toxicity and lack of experimental emphysema. *Am Rev Respir Dis*, 1981, 124, 613–618.
30. Lucey EC, Stone PJ. – Effect of chloromethyl ketone on the progression of elastase-induced emphysema in hamsters. *Am Rev Respir Dis*, 1982, 126, 174–175.

*Amélioration de l'emphysème induit par l'élastase neutrophilique humaine chez les hamsters grâce à un traitement préalable par un oligopeptide chlorométhyl cétone. E.C. Lucey, P.J. Stone, J.C. Powers, G.L. Snider.*

RÉSUMÉ: Les neutrophiles humains sont une source possible d'élastase responsable de la pathogénèse de l'emphysème pulmonaire humain. Une étude a cherché à déterminer si l'emphysème, induit chez les hamsters par un traitement intratrachéal au moyen d'élastase neutrophilique humaine (HNE), pouvait être amélioré par l'instillation intratrachéale de succinyl-alanyl-alanyl-prolyl-valine-chlorométhyl cétone (CMK). Un mg de CMK a été donné aux hamsters 1 heure avant l'administration de 300 ou 360 µg de HNE ou 1 heure ou encore 4 heures après 360 µg de HNE. Les animaux ont été étudiés 8 semaines après le traitement. CMK donné 4 heures après HNE n'améliore pas l'emphysème. Le CMK donné 1 heure avant HNE limite le développement de l'emphysème, mais non pas la métaplasie des cellules sécrétoires bronchiques. Une relation molaire de CMK/HNE instillés de 128 est nécessaire pour une efficacité de 50% dans l'amélioration de l'emphysème *in vivo*. Les études de clearance ont indiqué que 6.9% de CMK instillés pouvaient être lavés à partir des poumons 1 heure après l'instillation. Dès lors, une relation de 8.9 sur 1 molaire de CMK sur HNE lavable au moment de l'instillation de l'HNE entraîne une protection de 50%. Au cours d'expérimentations *in vitro* utilisant la <sup>3</sup>H-élastine comme substrat, une relation 3 sur 1 molaire de CMK sur HNE s'avère nécessaire pour inhiber 50% de l'activité élastolytique; 14% de l'activité persistent lorsqu'une relation molaire CMK sur HNE de 18 sur 1 est observée. L'étude de l'efficacité *in vivo* des anti-élastases, donnés comme prétraitement pour améliorer l'emphysème induit par HNE et la métaplasie des cellules glandulaires, est une expérimentation raisonnable, qui peut être utilisée comme étape dans l'évaluation de ces agents, en vue d'une utilisation possible pour la prévention de la maladie humaine.

*Eur Respir J.*, 1989, 2, 421–427.